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Purpose: Thrombocytopenia is not uncommonly encountered following active   anticoagulation 
of thromboembolism with unfractionated or even low-molecular-weight heparins. In this report, 
and utilizing a case study, we will address issues related to the diagnosis and treatment of 
heparin-induced thrombocytopenia (HIT) in a community-based clinical practice.
Methods: The case of a 73-year-old female patient who was recently diagnosed with 
gastroesophageal junction cancer and who developed left lower extremity deep vein thrombosis 
(DVT) while on active chemotherapy is presented. Following the initiation of anticoagulation, 
a significant drop in platelet counts was noted and a clinical diagnosis of HIT was made. Articles 
published in English addressing issues related to anticoagulation and thrombocytopenia were 
accessed from PubMed and are discussed.
Results: HIT is not uncommon, but its diagnosis can occasionally be difficult to confirm. 
Alternative anticoagulants might not be available for immediate use and many require special 
expertise for appropriate use. Fondaparinux, a synthetic pentasaccharide, is approved for active 
anticoagulation of DVT and pulmonary embolism and can be given once daily subcutaneously 
at a fixed dose with no need for monitoring. Many recent reports described the successful use 
of this agent in the treatment of HIT.
Conclusion: HIT can be difficult to diagnose; diagnostic tests are generally not available in 
most hospitals and the available ones lack the sensitivity and specificity needed to confirm 
such diagnosis. Additionally, the alternative anticoagulants are not widely available. In such 
circumstances, fondaparinux can be used as an alternative anticoagulant.
Keywords: anticoagulation, thrombosis, thrombocytopenia, heparin-induced   
thrombocytopenia
Case presentation
A 73-year-old female patient with multiple medical problems, including diabetes 
mellitus, hypertension, ischemic heart disease, and mild congestive heart failure, was 
recently diagnosed with gastroesophageal junction cancer for which she was started on 
5-flurouracil (5-FU) as a continuous infusion through a Hickman catheter, the   patency 
of which was maintained by regular heparin flushes.
The patient was admitted 2 weeks after chemotherapy infusion with few days’ 
history of progressive left calf pain and swelling. There was no associated trauma, joint 
pain, or fever. Physical exam confirmed left calf redness, hotness, tenderness, and 
swelling below the knee joint down to the ankle. A Doppler ultrasound confirmed Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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a diagnosis of left lower extremity deep vein thrombosis 
(DVT) involving the superficial and common femoral veins. 
Platelet counts 1 and 2 weeks earlier were 376 × 109/L and 
286 × 109/L, respectively. On admission the platelet counts 
were 103 × 109/L with a normal activated partial thrombo-
plastin time (aPTT) and international normalized ratio (INR). 
Patient was started on anticoagulation with unfractionated 
heparin (UFH).
The next day, however, platelet counts were noted to be 
low at 33 × 109/L. Work up for disseminated intravascular 
coagulation (DIC) including blood film, fibrinogen, and 
D-dimer were all negative. Both aPTT and INR were within 
normal limits, too. Further evaluation failed to show any 
new venous thrombosis, progression of the old thrombus, 
or arterial ischemia.
A clinical diagnosis of heparin-induced thrombocytopenia 
(HIT) was made, though laboratory tests to confirm such 
diagnosis were not available. Heparin infusion was stopped 
and a decision was made to anticogulate with fondaparinux 
7.5 mg subcutaneously once daily. Platelet counts, which 
were followed daily (Figure 1), started to improve 3 days 
later and normalized on day 6. The patient was discharged 
home on day 8 with normal counts.
Discussion
Thrombocytopenia during the course of anticoagulation 
with UFH or low-molecular-weight heparin (LMWH) is 
not an uncommon complication. Depending on its severity 
and underlying etiology, such thrombocytopenia can be a 
life- or limb-threatening complication. The patient under 
discussion had thrombocytopenia 13 days after UFH flushes 
were started through the Hickman catheter which dropped 
significantly a day after intravenous heparin infusion was 
started. Though this drop can be attributed to many factors, 
consumptive thrombocytopenia was less likely because of 
the size of the thrombus and absence of coagulopathy, but 
more   importantly, the platelet counts started the drop even 
before DVT was diagnosed. The patient did not have clini-
cal evidence or laboratory findings to support a diagnosis 
of DIC. The most likely cause of thrombocytopenia in this 
case was HIT.
HIT syndromes are of two types: type I is usually asso-
ciated with early-onset thrombocytopenia (within 4 days) 
and usually leads to a mild decrease in platelet count 
(rarely ,100 × 109/L). The patient typically recovers within 
3 days despite continued use of heparin. Type I results from 
nonimmune-mediated mechanisms through direct platelet 
activation by heparin. This type is a benign form of HIT and 
is usually not associated with any major clinical sequelae.1
Type II HIT, on the other hand, is usually induced by 
immunologic mechanisms, and typically occurs within 4 to 
14 days after exposure to heparin; however, it may occur 
earlier in patients previously exposed to heparin. A sub-
stantial fall in platelet count (but usually .20 × 109/L), can 
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Figure 1 Platelet count while on anticoagulation.
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occur with any dose, by any route, and has the potential to 
develop life-threatening venous or arterial thromboembolic 
complications that may manifest as myocardial infarction, 
cerebrovascular occlusion, skin necrosis, or limb ischemia. 
HIT tends to occur more with bovine- than porcine-derived 
heparin, more in females than males, and more in surgical 
than medical patients.2
Depending on the definition, severity of thrombocytope-
nia, and the form of heparin used, the frequency of HIT varies 
from as low as 1% to as high as 25%.3 A recent meta-analysis, 
however, reported a lower incidence of 2.6%.4
The diagnosis of HIT is difficult to confirm in many 
community hospitals. Table 1 lists some of the tests that 
can be used to help confirm such diagnosis; many are not 
available and difficult to perform. Except for the serotonin 
release assay, other tests lack the specificity and the sensitiv-
ity needed to establish such diagnosis.
Patients with type II HIT are at a high risk for thrombo-
sis and should be treated with an alternative anticoagulant 
therapy to reduce thrombotic complications. The current 
treatment of choice is one of the approved direct thrombin 
inhibitors, argatroban, lepirudin, bivalirudin, and danaparoid 
(Table 2). These drugs have been proven to be safe and effec-
tive in clinical studies.5,6 However, these drugs are not widely 
available in community hospitals and clinical experience in 
their use is usually lacking. We previously encountered a 
more complicated case leading to limb ischemia; lacking 
these drugs, we reported the use of plasmapheresis to create 
an artificial state of anticoagulation, exchanging the patient’s 
plasma with albumin rather than fresh frozen plasma, to allow 
safe introduction of warfarin.7
Fondaparinux
Fondaparinux, a synthetic pentasaccharide that specifically 
inhibits factor Xa activity, has been successfully used in 
many prophylaxis studies in medical, surgical, and patients 
undergoing major orthopedic procedures.8 This drug was 
also used in the active treatment of established venous 
thromboembolism (VTE). Two trials, MATISSE-DVT9 and 
MATISSE-PE,10 were similarly designed to demonstrate 
that fondaparinux was at least as effective and as safe as 
the current standard treatments for pulmonary embolism 
(PE) and DVT.
In MATTISSE-DVT, more than 2000 patients with 
confirmed acute symptomatic DVT were randomized to 
receive either a fixed once-daily dose of 7.5 mg fondaparinux 
subcutaneously (5.0 mg in patients ,50 kg and 10.0 mg in 
patients .100 kg) or twice-daily, weight-adjusted enoxaparin 
subcutaneously (1 mg/kg) for at least 5 days and until anti-
coagulation with warfarin was therapeutic. In an intention-
to-treat analysis, 43 (3.9%) of the 1098 fondaparinux-treated 
patients had symptomatic recurrent thromboembolic events, 
compared with 45 (4.1%) of the 1107 enoxaparin-treated 
patients (absolute difference, -0.15%; 95% CI -1.8% 
to 1.5%).9
MATISSE-PE included 2213 patients presenting with 
symptomatic PE. In this trial, patients were randomly 
assigned to receive either fondaparinux 7.5 mg subcutane-
ously or a dose-adjusted continuous intravenous infusion of 
UFH for at least 5 days. In an intention-to-treat analysis, the 
incidence of symptomatic recurrent VTE over the 3-month 
follow-up period was 3.8% in the fondaparinux group and 
5.0% in the UFH group (absolute difference -1.2%; 95% 
CI -3% to 0.5%).10
The two MATISSE studies demonstrate that fonda-
parinux used at a fixed dose of 7.5 mg once daily sub-
cutaneously can effectively and safely treat the acute 
phases of both PE and DVT. This would further simplify 
the treatment of both DVT and PE as no bodyweight 
adjustment is necessary and only a single subcutaneous 
injection per day is required. Based on these studies, fonda-
parinux is now approved for the active treatment of both   
DVT and PE.
Thrombocytopenia is not an issue  
with fondaparinux
None of the clinical studies that used fondaparinux at prophy-
lactic doses in orthopedic or general surgery, or in medical 
patients, or at higher doses used to treat DVT or PE, showed 
any significant thrombocytopenia.8
Table 1 Laboratory diagnosis of heparin-induced thrombocytopenia
Test Advantages Disadvantages Remarks
Serotonin release assay High sensitivity and specificity (.95%) High cost  
Technical experience
The gold-standard test
Heparin-induced platelet  
aggregation assay
Specificity .90% Low sensitivity
Solid phase ELISA immunoassay High sensitivity: 91% to .97%  
High negative predictive value
Low specificity: 74%–86% Test results are variable 
in dialysis patientsTherapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Table 2 Anticoagulants that can be used with heparin-induced thrombocytopenia
Drug Brand name Administration Monitoring Special issues
Lepirudin Refludan 0.10 mg/kg/h aPTT ratio:1.5–2.5 Cleared by the kidney, check for dosing  
with abnormal renal function
Bivalirudin Angiomax 0.15 mg/kg/h aPTT ratio:1.5–2.5 Dose adjustment is needed with hepatic   
and renal dysfunction
Argatroban Argatroban 2.0 μg/kg/min aPTT ratio:1.5–3.0 Dose adjustment is needed with hepatic   
but not with renal dysfunction
Fondaparinux Arixtra 7.5 mg sc daily not needed not approved by FDA for HIT
Danaparoid Orgaran Start at 400 units/h for 4 hours  
then decrease to 300 units/h for  
4 hours then 200 units/h thereafter
Anti-factor Xa level 10% cross reactivity with antibodies  
responsible for HIT, cleared by the  
kidney, long half-life
Abbreviations: aPTT, activated partial thromboplastin time; FDA, uS Food and Drug Administration; HIT, heparin-induced thrombocytopenia.
To identify whether fondaparinux could induce platelet 
aggregation in a HIT-positive test system, an aggregation 
assay was used in which platelet-rich plasma from normal 
donors was mixed with fondaparinux and the serum collected 
from clinically symptomatic HIT-positive individuals. In this 
model, fondaparinux at a final concentration of .20 times the 
therapeutic concentration did not induce aggregation, whereas 
UFH produced a 40% to 80% aggregation response.11
In another study, Warkentin and his group tested 
2726 patients for anti-PF4/heparin antibodies after they 
were randomized to receive antithrombotic prophylaxis with 
fondaparinux or LMWH (enoxaparin) following hip or knee 
surgery. Cross-reactivity of the IgG antibodies generated 
against PF4 in the presence of different anticoagulants, 
including UFH, LMWH, danaparoid, or fondaparinux, were 
also evaluated. The investigators found that anti-PF4/heparin 
antibodies were generated at similar frequencies in patients 
treated with fondaparinux or enoxaparin. Though antibod-
ies reacted equally well in vitro against PF4/UFH and PF4/
LMWH, none reacted against PF4/fondaparinux, leading to 
the conclusion that PF4/fondaparinux is recognized poorly 
by the antibodies generated, and suggesting that the risk of 
HIT with fondaparinux likely is very low.12
However, in at least 3 case reports, clinical HIT was seen 
after the use of fondaparinux, along with a strongly positive 
platelet serotonin release assay.13–15 Given the above, many 
case reports have described the successful use of fonda-
parinux in the management of patients with HIT.16–19
Conclusions
HIT is not uncommon. Diagnostic tests are generally not 
available in most hospitals and the available ones lack the 
sensitivity and specificity needed to confirm such diagnosis. 
Additionally, the alternative anticoagulants are not widely 
available and experience in their use is often lacking. In such 
circumstances, fondaparinux can be used as an alternative 
anticoagulant, after which warfarin can be safely introduced. 
Because heparins are a widely used medication and patients 
can be easily exposed to them, confirming such a diagnosis 
in a reference lab is recommended.
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